ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:
Hydrocortisone aceponate 0.584 mg/ml

For the full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Cutaneous spray, solution.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs.

4.2 Indications for use, specifying the target species

For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
For alleviation of clinical signs associated with atopic dermatitis in dogs.

4.3 Contraindications

Do not use on cutaneous ulcers.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals

Clinical signs of atopic dermatitis such as pruritus and skin inflammation are not specific for this disease and therefore other causes of dermatitis such as ectoparasitic infestations and infections which cause dermatological signs should be ruled out before treatment is started, and underlying causes should be investigated.

In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.

In the absence of specific information, the use in animal suffering from Cushing's syndrome shall be based on the risk-benefit assessment.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.

Total body surface treated should not exceed approximately 1/3 of the dog's surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders

and the thighs. See also section 4.10. Otherwise, use only according to the risk-benefit assessment of the responsible veterinary surgeon and subject the dog to regular clinical evaluations as further described in section 4.9.

Care should be taken to avoid spraying into the eyes of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

The active substance is potentially pharmacologically active at high doses of exposure.
The formulation may cause eye irritation following accidental ocular contact.
The formulation is flammable.

Wash hands after use. Avoid contact with eyes.
To avoid skin contact, recently treated animals should not be handled until the application site is dry.
To avoid inhalation of the product, apply the spray in a well-ventilated area.
Do not spray on naked flame or any incandescent material.
Do not smoke while handling the veterinary medicinal product.
Replace the bottle in the outer carton and in a safe place out of the sight and the reach of children immediately after use.

In case of accidental skin contact, avoid hand-to-mouth contact and wash the exposed area immediately with water.
In case of accidental eye contact, rinse with abundant quantities of water.
If eye irritation persists, seek medical advice.
In case of accidental ingestion, especially by children, seek medical advice immediately and show the leaflet or the label to the physician.

Other precautions

The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

4.6 Adverse reactions (frequency and seriousness)

Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Use only accordingly to the risk-benefit assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

No data available.
In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.

4.9 Amounts to be administered and administration route

Cutaneous use.
Before administration, screw the pump spray on the bottle.
The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm^2 of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm.

- For treatment of inflammatory and pruritic dermatoses, repeat the treatment daily for 7 consecutive days.
  In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
  If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.

- For alleviation of clinical signs associated with atopic dermatitis, repeat the treatment daily for at least 14 and up to 28 consecutive days.
  An intermediary control by the veterinarian at day 14 should be made to decide if further treatment is needed. The dog should be re-evaluated regularly with regard to HPA suppression or skin atrophy, both being possibly asymptomatic.
  Any prolonged use of this product, to control atopy, should be at the benefit risk assessment of the responsible veterinary surgeon. It should take place after a re-evaluation of the diagnosis and also a consideration of the multi-modal treatment plan in the individual animal.

Presented as a volatile spray, this veterinary medicinal product does not require any massage.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Tolerance studies of multiple doses were assessed over a period of 14 days in healthy dogs using 3 and 5 times the recommended dosage corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs (1/3 of the dog's body surface area). These resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.
In 12 dogs suffering from atopic dermatitis, after topical application once a day at the recommended therapeutic dosage for 28 to 70 (n=2) consecutive days, no noticeable effect on the systemic cortisol level was observed.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Corticosteroids, dermatological preparations.
ATCvet code: QD07AC16.

5.1 Pharmacodynamic properties

The veterinary medicinal product contains the active substance hydrocortisone aceponate.
Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis. In case of atopic dermatitis, improvement will be slower.

5.2 Pharmacokinetic particulars

Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids.
The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability. Hydrocortisone aceponate thus accumulates in the dog's skin allowing local efficacy at low dosage. The diesters are transformed inside the skin structures. This transformation is responsible for the potency of the therapeutic class. In laboratory animals, hydrocortisone aceponate is eliminated the same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces.
Topical application of diesters results in high therapeutic index: high local activity with reduced systemic secondary effects.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Propylene glycol methyl ether.

6.2 Major incompatibilities

None known.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life after first opening the immediate packaging: 6 months.

6.4. Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging

Box containing a polyethylene terephtalate (PET) or high density polyethylene (HDPE) bottle filled with 31 ml or 76 ml of solution, closed with an aluminium screw cap or a white plastic screw cap and a pump spray.

Carton box with a PET bottle of 31 ml
Carton box with a PET bottle of 76 ml
Carton box with a HDPE bottle of 31 ml
Carton box with a HDPE bottle of 76 ml

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

VIRBAC
1ère avenue 2065 m LID
06516 Carros

FRANCE

8. MARKETING AUTHORISATION NUMBER

EU/2/06/069/001
EU/2/06/069/002
EU/2/06/069/003
EU/2/06/069/004

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 09/01/2007
Date of latest renewal: 13/09/2011

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

VIRBAC
1ère avenue 2065 m LID
06516 Carros, France

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

C. STATEMENT OF THE MRLs

Not applicable.

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Not applicable.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton box with a bottle of 31 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
Hydrocortisone aceponate

2. STATEMENT OF ACTIVE SUBSTANCES

Hydrocortisone aceponate 0.584 mg/ml

3. PHARMACEUTICAL FORM

Cutaneous spray, solution.

4. PACKAGE SIZE

31 ml

5. TARGET SPECIES

Dogs.

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {MM/AA/AA}
Once opened, use by 6 months.

11. SPECIAL STORAGE CONDITIONS

Not applicable.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

VIRBAC
1ère avenue 2065 m LID
06516 Carros
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

Carton with a PET bottle of 31ml: EU/2/06/069/002
Carton with a HDPE bottle of 31ml: EU/2/06/069/003

17. MANUFACTURER'S BATCH NUMBER

Batch {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton box with a bottle of 76 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
Hydrocortisone aceponate

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Hydrocortisone aceponate 0.584 mg/ml

3. PHARMACEUTICAL FORM

Cutaneous spray, solution.

4. PACKAGE SIZE

76 ml

5. TARGET SPECIES

Dogs.

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {MM/AA/AA}
Once opened, use by 6 months.

11. SPECIAL STORAGE CONDITIONS

Not applicable.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

VIRBAC
1ère avenue 2065 m LID
06516 Carros
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

Carton box with a PET bottle of 76ml: EU/2/06/069/001
Carton box with a HDPE bottle of 76ml: EU/2/06/069/004

17. MANUFACTURER'S BATCH NUMBER

Batch {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Bottle of 76 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
Hydrocortisone aceponate

2. STATEMENT OF ACTIVE SUBSTANCES

Hydrocortisone aceponate 0.584 mg/ml

3. PHARMACEUTICAL FORM

Cutaneous spray, solution.

4. PACKAGE SIZE

76 ml

5. TARGET SPECIES

Dogs.

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Not applicable.

10. EXPIRY DATE

EXP {MM/AA/AA}

Once opened, use by 6 months.

11. SPECIAL STORAGE CONDITIONS

Not applicable.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

VIRBAC
1ère avenue 2065 m LID
06516 Carros
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

PET bottle of 76ml: EU/2/06/069/001
HDPE bottle of 76ml: EU/2/06/069/004

17. MANUFACTURER'S BATCH NUMBER

Batch {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Bottle of 31 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
Hydrocortisone aceponate

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Hydrocortisone aceponate 0.584 mg/ml.

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

31 ml

4. ROUTE(S) OF ADMINISTRATION

Cutaneous use.

5. WITHDRAWAL PERIOD(S)

Not applicable.

6. BATCH NUMBER

Lot {number}

7. EXPIRY DATE

EXP {month/year}
Once opened, use by 6 months.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer:

VIRBAC
1ère avenue 2065 m LID
06516 Carros
FRANCE

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
Hydrocortisone aceponate

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Hydrocortisone aceponate 0.584 mg/ml.

4. INDICATIONS

For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
For alleviation of clinical signs associated with atopic dermatitis in dogs.

5. CONTRAINDICATIONS

Do not use on cutaneous ulcers.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Cutaneous use.
Before administration, screw the pump spray on the bottle.
The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm^2 of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm.

- For treatment of inflammatory and pruritic dermatoses, repeat the treatment daily for 7 consecutive days.
  In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
  If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.

- For alleviation of clinical signs associated with atopic dermatitis, repeat the treatment daily for at least 14 and up to 28 consecutive days.
  An intermediary control by the veterinarian at day 14 should be made to decide if further treatment is needed. The dog should be re-evaluated regularly with regard to HPA suppression or skin atrophy, both being possibly asymptomatic.
  Any prolonged use of this product, to control atopy, should be at the benefit risk assessment of the responsible veterinary surgeon. It should take place after a re-evaluation of the diagnosis and also a consideration of the multi-modal treatment plan in the individual animal.

9. ADVICE ON CORRECT ADMINISTRATION

Presented as a volatile spray, this veterinary medicinal product does not require any massage.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Shelf-life after first opening the container: 6 months.

12. SPECIAL WARNING(S)

Special precautions for use in animals:

Clinical signs of atopic dermatitis such as pruritus and skin inflammation are not specific for this disease and therefore other causes of dermatitis such as ectoparasitic infestations and infections which cause dermatological signs should be ruled out before treatment is started, and underlying causes should be investigated.

In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.

In the absence of specific information, the use in animal suffering from Cushing's syndrome shall be based on the risk-benefit assessment.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.

Total body surface treated should not exceed approximately 1/3 of the dog's surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. See also section "Overdose". Otherwise, use only according to the risk-benefit assessment of the responsible veterinary surgeon and subject the dog to regular clinical evaluations as further described in section "Dosage for each species, route(s) and method of administration".

Care should be taken to avoid spraying into the eyes of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The active substance is potentially pharmacologically active at high doses of exposure.
The formulation may cause eye irritation following accidental ocular contact.
The formulation is flammable.

Wash hands after use. Avoid contact with eyes.
To avoid skin contact, recently treated animals should not be handled until the application site is dry.
To avoid inhalation of the product, apply the spray in a well-ventilated area.
Do not spray on naked flame or any incandescent material.
Do not smoke while handling the veterinary medicinal product.
Replace the bottle in the outer carton and in a safe place out of the sight and the reach of children immediately after use.

In case of accidental skin contact, avoid hand-to-mouth contact and wash the exposed area immediately with water.
In case of accidental eye contact, rinse with abundant quantities of water.
If eye irritation persists, seek medical advice.
In case of accidental ingestion, especially by children, seek medical advice immediately and show the leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Use only accordingly to the risk-benefit assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.

Overdose (symptoms, emergency procedures, antidotes):

Tolerance studies of multiple doses were assessed over a period of 14 days in healthy dogs using 3 and 5 times the recommended dosage corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs (1/3 of the dog's body surface area). These resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.
In 12 dogs suffering from atopic dermatitis, after topical application once a day at the recommended therapeutic dosage for 28 to 70 (n=2) consecutive days, no noticeable effect on the systemic cortisol level was observed.

Other precautions:

The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

15. OTHER INFORMATION

Hydrocortisone aceponate administered topically accumulates and is metabolised in skin, as suggested by radioactivity distribution studies and pharmacokinetic data. This results in minimal amounts to reach the blood stream. This particularity will increase the ratio between the desired local anti-inflammatory effect in the skin and the undesirable systemic effects.

Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.

Pack sizes:
Carton box with a PET bottle of 31 ml
Carton box with a PET bottle of 76 ml
Carton box with a HDPE bottle of 31 ml
Carton box with a HDPE bottle of 76 ml

Not all pack size may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

AT: Österreich
VIRBAC Österreich GmbH
Hildebrandgasse 27
1180 Wien
Österreich
Tel: +43-(0)1 21 834 260

BE: België/Belgique
VIRBAC Belgium NV
Esperantolaan 4
3001 Leuven
België / Belgique / Belgien
Tel: +32-(0)16 387 260

BG: Република България
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Франция
Тел: +33-(0)4 92 08 73 00

CY: Κύπρος
VIRBAC Hellas SA
13ο χλμ Ε.Ο. Αθηνών – Λαμίας,
Τ.Κ.14452, Μεταμόρθωζη,
Ελλάδα
Τηλ. : +30-210 6219520
info@virbac.gr

CZ: Česká republika
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Francie
Tel: +33-(0)4 92 08 73 00

DE: Deutschland
VIRBAC Tierarzneimittel GmbH
Rögen 20
23843 Bad Oldesloe
Deutschland
Tel: +49-(4531) 805 111

DK: Danmark
VIRBAC Danmark
A/S Profilvej 1 6000
Kolding
Danmark
Tel: +45 75521244

EE: Eesti
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Prantsusmaa
Tel: +33-(0)4 92 08 73 00

ES: España
VIRBAC España SA
Angel Guimerá 179-181
08950 Esplugues de Llobregat (Barcelona)
España
Tel. : + 34-(0)93 470 79 40

FI: Suomi/Finland
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Ranska
Tel: + 33-(0)4 92 08 73 00

FR: France
VIRBAC France
13e rue LID
06517 Carros
France
service-conso@virbac.fr

GR: Ελλάδα
VIRBAC Hellas SA
13ο χλμ Ε.Ο. Αθηνών – Λαμίας,
Τ.Κ.14452, Μεταμόρθωζη,
Ελλάδα
Τηλ. : +30-210 6219520
info@virbac.gr

HR: Hrvatska
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Francuska
Tel: + 33-(0)4 92 08 73 00

HU: Magyarország
VIRBAC Hungary KFT
Szent Istvàn krt.11.II/21.
1055 Budapest
Magyarország
Тел: +36703387177

IE: Ireland
VIRBAC
1ère avenue 2065 m LID
06516 Carros
France
Tel: + 33 (0) 4 92 08 73 00

IS: Ísland
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Frakkland
Tel: + 33-(0)4 92 08 73 00

IT: Italia
VIRBAC SRL
Via Ettore Bugatti, 15
20142 Milano
Italia
Tel: + 39 02 40 92 47 1

LT: Lietuva
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Prancūzija
Tel: +33-(0)4 92 08 73 00

LU: Luxembourg/Luxemburg
VIRBAC Belgium NV
Esperantolaan 4
3001 Leuven
Belgique / Belgien
Tel: +32-(0)16 387 260

LV: Latvija
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Francija
Tel: +33-(0)4 92 08 73 00

MT: Malta
VIRBAC
1ère avenue 2065 m LID
06516 Carros
Franza
Tel: + 33-(0)4 92 08 73 00

NO: Norge
VIRBAC Danmark A/S
Profilvej 1
6000 Kolding Danmark
Tel: + 45 75521244

PT : Portugal
VIRBAC de Portugal Laboratórios LDA
R.do Centro Empresarial
Ed13-Piso 1- Esc.3
Quinta da Beloura
PT-2710-693 Sintra
Tel: + 351 219 245 020

SI: Slovenija
VIRBAC
1ère avenue 2065 m LID
FR-06516 Carros
Francija
Tel : + 33-(0)4 92 08 73 00

SE: Sverige
VIRBAC Danmark A/S Filial Sverige
SE-171 21 Solna
Tel: +45 75521244

NL: Nederland
VIRBAC Nederland BV
Hermesweg 15
3771 ND-Barneveld
Nederland
Tel : +31-(0)342 427 127

PL: Polska
VIRBAC Sp. z o.o.
ul. Puławska 314
02 - 819 Warszawa
Polska
Tel.: + 48 22 855 40 46

RO : România
VIRBAC
1ère avenue 2065 m LID
FR-06516 Carros
Franța
Tel: + 33-(0)4 92 08 73 00

SK: Slovenská republika
VIRBAC
1ère avenue 2065 m LID
FR-06516 Carros
Francúzsko
Tel: + 33-(0)4 92 08 73 00

UK: United Kingdom (Northern Ireland)
VIRBAC
1ère avenue 2065 m LID
FR-06516 Carros
France
Tel: +33-(0)4 92 08 73 00